Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Confederación de la Producción y del Comercio (CPC) | UNKNOWN |
| Bolsa de Santiago | UNKNOWN |
Not provided
Not provided
Not provided
COVID-19 infection has spread worldwide causing several deaths in few months Convalescent Plasma from COVID 19 donors has shown huge activity in small series from Chinese patients and currently many centers from USA and the European Union are assessing its use looking to avoid mortality and prolonged hospitalizations COVID-19-related
This is a collaborative, 4 arms , non randomized clinical trial assessing the use of Convalescent Plasma from COVID-19 recovered donors to be used in oncological and non-oncological patients with current severe COVID-19 infection or in patients with risk factors of major complications secondary to COVID-19 infection
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cancer patients with COVID 19 infection and severity criteria | Experimental | All patients will be treated with 1 or more convalescent plasma units |
|
| Cancer patients with COVID 19 infection and risk factors | Experimental | All patients will be treated with 1 or more convalescent plasma units |
|
| Non-Cancer patients COVID 19 infection and severity criteria | Experimental | All patients will be treated with 1 or more convalescent plasma units |
|
| Non-cancer patients COVID 19 (+) and risk factors | Experimental | All patients will be treated with 1 or more convalescent plasma units |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Convalescent Plasma from COVID-19 donors | Biological | Patients that will participate in this clinical trial will be treated with Convalescent Plasma from COVID-19 donors regardless of the arm where they will be included |
| Measure | Description | Time Frame |
|---|---|---|
| in-hospital mortality secondary to COVID-19 among patients treated with convalescent plasma | in-hospital mortality secondary to COVID-19 among patients treated with convalescent plasma | 1 year |
| safety of the use of convalescent plasma drom COVID 19 donors | safety of convalescent plasma from COVID 19 donors (CTCAE V5.0) | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Mortality at 30 days, 90 days, 6 months and 1 year | any cause of mortality during these periods | 1 year |
| in-hospital Mortality COVID-19 related compared with non-treated population according to Chilean official reports |
Not provided
Inclusion Criteria:
For all patients:
A. Patient must sign an informed consent to participate in this trial
B. Signed consent to participate in this trial must be given not after 14 days from the first day of symptoms COVID-19 related
Patients with severity criteria must have any of the following: dyspnea and or respiratory rate >=30 per min and or saturation <= 93% with fraction of inspired oxygen 21% and or ratio of partial pressure arterial oxygen and fraction of inspired oxygen (PaFi )<300 and or lung images showing worsening in 24-48 hours
or
Patients without severity criteria but with 2 or more factor risks:
A. 50 years or older
B. any of the following comorbidities: Diabetes Mellitus, Hypertension, Chronic Obstructive Pulmonary Disease, Chronic Kidney Failure, non-oncological related chronic immunosuppression
C. Total bilirubin>1,2 mg/dl or Blood Urea Nitrogen> 20 mg/dl or Lactate Dehydrogenase>245 U/L
D. D-dimer > 1mg/L
E. Neutrophils 7.3 x 10³ or greater and or Lymphocytes lesser than 0,8 x 10³ µl
F. C reactive protein >9,5 mg/dl and ferritin > 300 ug/ml
G. Interleukin-6 >7 pg/mL
H. antineoplastic treatment such as radiotherapy- cytotoxic chemotherapy- immunotherapy- molecular therapy- oncological surgery during the last 8 weeks
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Christian Caglevic, MD | Contact | 56981369487 | christian.caglevic@falp.org |
| Name | Affiliation | Role |
|---|---|---|
| Raimundo Gazitua, MD | Fundacion Arturo Lopez Perez | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Fundacion Arturo Lopez Perez | Recruiting | Providencia | Santiago Metropolitan | 7500921 | Chile |
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | Sep 11, 2021 | |
| Reset | Sep 23, 2021 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Sep 11, 2021 | Sep 23, 2021 |
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Multicenter, non-randomized, 4 arms
Not provided
Not provided
Not provided
Not provided
based on results from this trial comparing with official information
| through study completion, an average of 1 year |
| Number of days of hospitalization in high complexity facilities after convalescent plasma use | number of days of hospitalization in high complexity facilities after convalescent plasma use | 1 year |
| Number of days of hospitalization in intensive care unit after convalescent plasma use | number of days of hospitalization in intensive care unit after convalescent plasma use | 1 year |
| Number of days of mechanical ventilatory support in patients after convalescent plasma use | number of days of mechanical ventilatory support in patients after convalescent plasma use | 1 year |
| Total number of days of mechanical ventilatory support | total number of days of mechanical ventilatory support | 1 year |
| Total number of hospitalization days in patients treated with convalescent plasma | total number of hospitalization days in patients treated with convalescent plasma | 1 year |
| Number of hospitalization days in patients after treatment with convalescent plasma | total number of hospitalization days in patients after treatment with convalescent plasma | 1 year |
| Viral load measuring | Viral load measuring | 14 days |
| Immunological response in treated patients (COVID19-Immunoglobulin M and Immunoglobulin G, neutralizing antibodies) | COVID19-Immunoglobulin M and Immunoglobulin G, neutralizing antibodies | day 1 of hospitalization |
| Negativization of COVID 19 load since convalescent plasma use | negativization of COVID 19 load since convalescent plasma use | 14 days |
| Negativization of COVID 19 load since hospitalization | negativization of COVID 19 load since hospitalization | 14 days |
| Negativization of COVID 19 load since first reported symptoms COVID-19 related | negativization of COVID 19 load since first reported symptoms COVID-19 related | 14 days |
| Donor Interferon Gamma profile characterization | Interferon Gamma measurement from donor | 1 day |
| Donor Granulocyte Macrophage Colony Stimulating Factor characterization | Granulocyte Macrophage Colony Stimulating Factor measurement from donor | 1 day |
| Donor Tumor Necrosis Factor Alfa characterization | Tumor Necrosis Factor Alfa measurement from donor | 1 day |
| Donor Interleukin -1 beta characterization | Interleukin -1 beta measurement from donor | 1 day |
| Donor Interleukin-2 characterization | Interleukin -2 measurement from donor | 1 day |
| Donor Interleukin-4 characterization | Interleukin -4 measurement from donor | 1 day |
| Donor Interleukin-6 characterization | Interleukin -6 measurement from donor | 1 day |
| Donor Interleukin-8 characterization | Interleukin -8 measurement from donor | 1 day |
| Donor Interleukin-10 characterization | Interleukin -10 measurement from donor | 1 day |
| Receptor Interferon Gamma profile characterization | Interferon Gamma measurement from receptor | 1 day |
| Receptor Granulocyte Macrophage Colony Stimulating Factor characterization | Granulocyte Macrophage Colony Stimulating Factor measurement from receptor | 1 day |
| receptor Tumor Necrosis Factor Alfa characterization | Tumor Necrosis Factor Alfa measurement from receptor | 1 day |
| receptor Interleukin -1 beta characterization | Interleukin -1 beta measurement from receptor | 1 day |
| Receptor Interleukin-2 characterization | Interleukin -2 measurement from receptor | 1 day |
| Receptor Interleukin-4 characterization | Interleukin -4 measurement from receptor | 1 day |
| Receptor Interleukin-6 characterization | Interleukin -6 measurement from receptor | 1 day |
| Receptor Interleukin-8 characterization | Interleukin -8 measurement from receptor | 1 day |
| Receptor Interleukin-10 characterization | Interleukin -10 measurement from receptor | 1 day |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |